Best Oncology Companies in Los Angeles, United States
The 37 best Oncology companies in Los Angeles, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TORL BioTherapeutics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Los Angeles
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 11 mo ago | — | Mark Attanasio Co-Founder | — | — |
| 2 | Kite Pharma Developer of cancer immunotherapy products using genetic engineering | $98M | 101 mo ago | 17 | — | 1,184 patents Engineering CAR‑T cells and immune‑cell therapies with novel receptors, vectors, and modulators | — |
| 3 | Puma Biotechnology Developer of tyrosine kinase inhibitor for the treatment of breast cancer | $60M | 54 mo ago | 193 193 → 258 (+34%) | — | — | — |
| 4 | ImaginAb Immune imaging technology for cancer and autoimmune disease management | $60M | 63 mo ago | 17 17 → 12 (-29%) | — | 131 patents Therapeutic antibodies targeting immune cell receptors and tumor-specific antigens | — |
| 5 | Trethera Developer of small molecule cancer therapeutics that target DNA replication and integrity 29Funding top 30%Patents top 37%Moat top 37%Product top 41% All 9 signals ▾Fundingtop 30% Patentstop 37% Moattop 37% Producttop 41% Innovationtop 42% Techtop 47% Talentbottom 49% Globalbottom 33% Marketbottom 18% Funding: Raised $31.0M across 20 rounds · 20 rounds over 11 yrs (1.8/yr) Patents: 15 patents matched (strict assignee match) · 15 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 11 mo ago | 3 | Ken Schultz Chairman & CEO | 15 patents Solid-state pharmaceutical forms of deoxycytidine kinase inhibitor drugs | — |
| 6 | Aadi Bioscience Precision medicine company improving lives with mTOR-driven disease therapies | $23M | 18 mo ago | 95 | Neil Desai CEO & Chairman | — | — |
| 7 | NeOnc Technologies Developer of drug delivery methods for pharma-based therapeutics | $19M | 13 mo ago | 4 | — | 48 patents Monoterpene-derived anticancer pharmaceuticals, especially perillyl alcohol derivatives for cancer therapy. | — |
| 8 | LadRx Corp Developer of therapeutics for neurodegenerative diseases and cancer | $10M | 62 mo ago | 3 | — | 17 patents Albumin-targeted drug conjugates and radiolabeled imaging agents for controlled delivery | — |
| 9 | Fuse Biotherapeutics Developer of immune-modulating therapies for the treatment of cancer | $10M | 58 mo ago | 12 | Paul Song Md Co-Founder & Senior Advisor | 32 patents Cytokine fusion protein therapeutics for immune modulation and targeted biologic therapies | — |
| 10 | Arrogene Developer of cancer therapeutics based on a nanotechnological targeting platform | $9M | 82 mo ago | — | Larry Couture Chief Executive Officer | 5 patents Polymeric drug delivery systems and antisense glioma therapeutics using polymalic acid. | — |
| 11 | Immix Biopharma Developer of therapeutics for amyloidosis, autoimmune diseases, and oncology indications 53Product top 14%News top 24%Growth top 32%Funding top 34% All 12 signals ▾Producttop 14% Newstop 24% Growthtop 32% Fundingtop 34% Innovationtop 39% Patentstop 41% Moattop 45% Techtop 47% Fin. healthtop 49% Talentbottom 49% Marketbottom 38% Globalbottom 36% Product: 5 distinct product lines · Company stage: Public News: 5 BI events in 12 mo (of 16 tracked, 7 types) · +150% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 12 mo ago | 11 | Ilya Rachman Co-Founder & CEO | 25 patents Targeted nanoparticle delivery of therapeutics for cancer and inflammatory diseases | — |
| 12 | Immungene Specializes in antibody engineering to develop new therapeutics for cancer and other diseases | $9M | 154 mo ago | 3 | Sanjay Khare CEO & President | 45 patents Antibody‑interferon fusion biologics for targeted cancer immunotherapy | — |
| 13 | Cognos Therapeutics Provider of an implantable device designed to deliver therapeutic drugs | $6M | 59 mo ago | 13 | Frank Adell CEO | — | — |
| 14 | Transonic Imaging Ultrasound-based 3D imaging technology | $5M | 93 mo ago | — | Vasilis Marmarelis Founder | — | — |
| 15 | Kairos Pharma Developer of T-cell therapies against cancer and drug resistance | $4M | 20 mo ago | 3 | — | — | — |
| 16 | Symphony Biosciences Developer of drugs to treat solid tumors | $2M | 19 mo ago | 4 | Manish Butte Co-Founder | — | — |
| 17 | Cytomag Microfluidic systems for cell isolation and analysis primarily for the detection and analysis of circulating… | $2M | 143 mo ago | — | Matthew Kerby Founder & CEO | — | — |
| 18 | Bexa Provider of a device for breast examination in women | $2M | 21 mo ago | — | Joe Peterson CEO | — | — |
| 19 | EntroGen Molecular diagnostic solutions for oncology, hematology, automation, reagents, and software | $286K | 157 mo ago | 20 | — | — | — |
| 20 | Vault Pharma Multi-IND biotech pioneering vault technology for targeted immune signaling and therapeutics | $225K | 117 mo ago | 4 | — | — | — |
Top 12 Oncology companies in Los Angeles
#1
Series C · Los Angeles, California · founded 2019$350Mraised▾
Developer of antibody-based therapeutics for the treatment of cancer. The company's lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate for patients across multiple cancer types. Also, it is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications.
- Oct 2025Series C$96M
- Apr 2024Series B$158.3M
- Apr 2023Series B$158M
#2
Series C · Los Angeles, California · founded 2013 · 3 employees$31Mraised▾
Developer of small molecule cancer therapeutics that target DNA replication and integrity. Its lead compounds target metabolic pathways that control DNA replication and signal transduction pathways that allow cells to repair DNA damage. Its lead candidate is a deoxycytidine kinase inhibitor that is currently under investigation for leukemia and solid tumors.
- Sep 2025Grant (prize money)$1.8M
- Sep 2025Grant (prize money)$610.9K
- Aug 2025Grant (prize money)$2M
- Aug 2025Grant (prize money)$995K
#3
Public · Los Angeles, California · founded 2008 · 4 employees$18.7Mraised▾
Developer of drug delivery methods for pharma-based therapeutics. The company develops intranasal inhalation of perillyl alcohol for the treatment of malignant brain cancer (gliomas). The company has secured worldwide rights to NEO100, a purified version of perillyl alcohol, and has obtained approval from the FDA to perform clinical trials in patients with recurrent Grade 4 glioma.
- Aug 2025Grant (prize money)$2.5M
- Jul 2024Series A$18.3M
- Feb 2022Seed$50K
- Feb 2013Seed$24.8K
#4
Public · Los Angeles, California · founded 2012 · 11 employees$9.1Mraised▾
Developer of therapeutics for amyloidosis, autoimmune diseases, and oncology indications. The company's product line include NXC-201, a BCMA-targeting CAR-T therapy for relapsed/refractory AL amyloidosis, multiple myeloma, and autoimmune disease and IMX-110 for solid tumors like soft tissue sarcoma.
- Sep 2025Post IPO$9.1M
- Aug 2017Series A—
#5
Public · Los Angeles, California · founded 2008 · 95 employees$23Mraised▾
Precision medicine company improving lives with mTOR-driven disease therapies. The company focuses on realizing the potential of mTOR inhibition through precision medicine and albumin-bound nanoparticle technology. It aims to improve the lives of people with mTOR-driven diseases by addressing the limitations of current mTOR inhibitors. The company leverages genomic profiling technology to identify patients most likely to benefit from mTOR inhibition. The company is dedicated to advancing therapies for advanced malignant PEComa and other pipeline opportunities. The company is committed to patient advocacy and providing resources for healthcare professionals. The company is a pharmaceutical company focused on research and development of targeted therapies.
- Mar 2025Post IPO$100M
- Sep 2022Post IPO$72.5M
- Jul 2017Grant (prize money)$2M
- May 2017Series A$23M
#6
Public · Los Angeles, California · founded 2016 · 3 employees$3.5Mraised▾
Developer of T-cell therapies against cancer and drug resistance
- Jan 2025Post IPO$3.5M
#7
Deadpooled · Los Angeles, California · founded 2021 · 4 employees$2.4Mraised▾
Developer of drugs to treat solid tumors. The company's first product is SymphNode, a biodegradable drug combination administered at the time of surgery to attack malignant cells and overcomes barriers created by the tumor microenvironment.
- Jan 2025Grant (prize money)$2.4M
#8
Early Stage · Los Angeles, California · founded 1997$1.6Mraised▾
Provider of a device for breast examination in women. It offers a device that employs high resolution elastography to produce a map of abnormal breast tissues and masses to detect breast cancer. It integrates AI-based platform for the evaluation of all discovered breast masses using B-mode ultrasound and classification of abnormal breast tissues.
- Dec 2024Unattributed$6M
- Dec 2015Unattributed$1.6M
#9
Series C · Los Angeles, California · founded 2007 · 17 employees$59.6Mraised▾
Immune imaging technology for cancer and autoimmune disease management. They re-engineer therapeutic antibodies against biologically important targets into small proteins optimized for diagnostic imaging with Positron Emission Tomography (PET). They aim to use their companion in-vivo diagnostics to help realize the promise of personalized medicine. This noninvasive imaging approach has been validated across several pharmaceutical-partnered immune programs and through their proprietary imaging program for prostate cancer.
- Jun 2021Series C$12.8M
- Sep 2017Series B$8M
- Apr 2016Series B$5.3M
- May 2014Series B$21M
#10
Public · Los Angeles, California · founded 2010 · 193 employees$60Mraised▾
Developer of tyrosine kinase inhibitor for the treatment of breast cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
- Mar 2022Post IPO—
- May 2017Post IPO—
- Dec 2011Series C$5M
- Oct 2011Series C$55M
#11
Acquired · Los Angeles, California · founded 2009 · 17 employees$97.7Mraised▾
Developer of cancer immunotherapy products using genetic engineering. The company's product Yescarta a CAR-T therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma and TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
- Apr 2018Post IPO$300M
- Jan 2015Post IPO$60M
- Dec 2014Post IPO$188M
- May 2014Series B$50M
#12
Series A · Los Angeles, California · founded 2015 · 13 employees$5.7Mraised▾
Cognos Therapeutics is developing solutions for the diagnosis and treatment of neuropathic diseases. The company is developing Sinnais, a standalone, implantable device designed to deliver therapeutic drugs locally and metronomically to the desired area. It is made of biocompatible and MRI-compatible materials. Application areas include tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.
- Oct 2021Series A$55.2K
- Jul 2021Series A$600K
- May 2021Series A$3.8M
- Dec 2020Seed$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Editas Medicine47
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.